Myopathy clinical trials at UCSD
1 research study open to eligible people
A Study of the Efficacy and Safety of 24 Week Treatment With REN001 in Patients With Primary Mitochondrial Myopathy
open to eligible people ages 18 years and up
This is a randomized, double-blind, placebo-controlled, parallel group, multi-centre, study designed to investigate the efficacy and safety of REN001 administered once daily over a 24-week period to patients with PMM.
La Jolla, California and other locations